Published in final edited form as:

Circ Cardiovasc Qual Outcomes. 2015 March ; 8(2 Suppl 1): S48–S51. doi:10.1161/CIRCOUTCOMES.115.001700.

“Frailty, Thy Name Is Woman” Syndrome of Women With Heart Failure With Preserved Ejection Fraction

Dawn M. Pedrotty, MD, PhD and Mariell Jessup, MD

Cardiovascular Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia

Heart failure (HF) is the most common cause for hospitalization among patients aged 65 years, affecting ~6 million Americans; at 40 years, American men and women have a 1 in 5 lifetime risk of developing HF.¹ There are 2 distinct HF phenotypes: a syndrome with normal or near-normal left ventricular ejection fraction (LVEF) referred to as HF with preserved EF (HFpEF)² and the phenotype associated with poor cardiac contractility or HF with reduced EF (HFrEF). HFrEF is frequently caused by coronary artery disease with a male predominance; evidence-based strategies have been established for more than a decade. In contrast, the precise clinical criteria for HFpEF are not universally agreed on, the syndrome disproportionally affects women in 2:1 ratio, and there are no proven treatments.^{3–5} There are some commonalities between HFrEF and HFpEF in addition to the classic symptoms of breathlessness, edema, and fatigue: older age, diabetes mellitus, and a history of valvular disease are risk factors that are predictive of both clinical phenotypes.⁶ Risk factors associated with HFpEF include female sex, especially women with diabetes mellitus,⁷ higher body mass index, smoking, hypertension, concentric LV hypertrophy (LVH), and atrial fibrillation (AF).^{6,8,9} Risk factors associated with HFrEF include male sex, higher total cholesterol and heart rate, eccentric LVH, coronary artery disease, and left bundle-branch block.^{6,9}

Evolution of the HFpEF Definition

A remarkable lack of consensus exists with respect to the phenotypic characteristics of HFpEF, as evidenced by the divergent definitions of the European Study Group on Diastolic Heart Failure,¹⁰ the Framingham Group,¹¹ and the European Society of Cardiology,¹² to name just a few (Table).¹³ All include symptoms or signs but vary in specificity and a requirement for objective data. The definition of preserved LVEF is also inconsistent but typically defined as >50%.¹³ The most important consequence of this variability is that the inclusion criteria for large, clinical HFpEF trials are likewise inconsistent and contribute to the heterogeneity of the results.¹³ Several important recent HFpEF trials underscore the above inconsistencies: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT), Candesartan in Heart Failure Assessment of Reduction

Correspondence to Mariell Jessup, MD, Cardiovascular Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 2 East Perelman Pavilion, 3400 Civic Center Blvd, Philadelphia, PA 19104. jessupm@uphs.upenn.edu.

Disclosures

None.

in Mortality and Morbidity (CHARM-Preserved), and Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). TOPCAT included patients aged 50 years with HFpEF, diagnosed by signs and symptoms in conjunction with previous hospital admission or elevated brain natriuretic peptide level with an LVEF of >45%. This study showed no improvement with spironolactone on a composite of cardiovascular mortality, cardiac arrest, or hospitalization for HF.¹⁴ CHARM-Preserved included patients with New York Heart Association II–IV HF and LVEF >40%; the results showed no significant benefit of candesartan on cardiovascular death or hospital admission for HF.¹⁵ I-PRESERVE included patients with New York Heart Association II–IV and an LVEF of 45% and a hospitalization for HF in the previous 6 months. Again, there was no significant improvement with irbesartan on a composite outcome of death from any cause or hospitalization for a cardiovascular cause.¹⁶

Accordingly, there has been growing interest in the development of criteria for specific subsets of HFpEF, a syndromal disease where multiple cardiac and vascular abnormalities exist. HFpEF is associated with ventricular dysfunction (impaired relaxation and impaired filling), atrial enlargement and dysfunction, autonomic dysregulation and chronotropic incompetence affecting exercise tolerance, vascular reactivity and stiffening, and dynamic mitral regurgitation. Patients with HFpEF are typically hypertensive, diabetic, obese, older, and deconditioned.¹³ Moreover, when important morbidities of the elderly coexist in patients with HFpEF, such as renal insufficiency,¹⁷ iron deficiency or anemia,¹⁸ and chronic obstructive lung disease,¹⁹ poor outcomes become even worse. Given the confounding effect of a complex set of risk factors and comorbidities, matching treatment interventions to a specific patient's phenotype in HFpEF is a promising approach and may increase the chance of showing clinical benefit with targeted therapies. The question arises as how to best group patients.

One approach is to implement phenomapping, identifying phenotypically distinct HFpEF categories and developing a classification system to group together pathophysiologically similar individuals who may respond in a more homogeneous, predictable way to intervention. A recent study by Shah et al²⁰ identified 3 clinical phenogroups from a HFpEF cohort with shared diagnostic features: group 1, younger patients with moderate diastolic dysfunction who had relatively normal brain natriuretic peptide; group 2, obese and diabetic patients with a high prevalence of obstructive sleep apnea and ventricular relaxation abnormalities; and group 3, older patients with significant chronic kidney disease, electric (longest QRS duration and largest QRS-T angle) and myocardial remodeling (highest relative wall thickness, LV mass index, and highest E/e' ratio), pulmonary hypertension, and right ventricular dysfunction. Perhaps not surprisingly, these groupings were an independent predictor of differential outcomes.²⁰ Other studies have examined geographic variation in outcomes observed in HFpEF trials highlighting not only the differences in hospitalization criteria in different regions but also the possibility of racial, ethnic, or even environmental determinants on health end points.^{21,22} Still, other investigations have developed cohorts stratified by specific comorbidities, including renal function,²³ right heart function,²⁴ and diabetes mellitus.²⁵ Lindman et al²⁵ asked whether diabetic patients with HFpEF had distinctive characteristics and outcomes from those of nondiabetic patients. As might be predicted, diabetic patients with HFpEF had a more severe disease phenotype with higher

comorbidities, increased LVH, and elevated serum markers for vasoconstriction, oxidative stress, inflammation, and fibrosis. Diabetic patients comprise $\approx 30\%$ to 40% of the HFpEF population; this phenotype subgroup seems appropriate. But it only serves to further confuse the diagnostic criteria for HFpEF. What components of the diabetes mellitus syndrome contribute to the cardiac disorder and should be classified: duration of diabetes mellitus, extent of diabetic control, age at onset, etc? If age proves to be an important criterion for grouping, are we certain years of age are not a surrogate for some physiological marker of severity? More importantly, this form of phenotyping may not serve to identify the mechanisms responsible for the actual pathophysiology of the HFpEF syndrome.

Can Phenotypes of HFpEF Provide Pathophysiological Insights?

Another option would be to focus on a known physiological difference that might shed light on pathological mechanisms, for example, sex. Women are disproportionately affected with HFpEF; it has long been recognized that at puberty, even normal hearts are different between the sexes. Distinctions in cardiac structure between men and women include LV chamber size and mass that are 15% to 40% lower in women, even after adjustment for smaller body type.^{26,27} There are fundamental differences in structural remodeling in response to chronic load, either from aortic stenosis or from hypertension. Men are more likely to develop eccentric LVH, whereas women develop concentric LVH. Interestingly, regression of LVH is more pronounced in women after aortic valve replacement, suggesting that women have a greater sensitivity to pressure overload.^{28,29} Importantly, the greater reversibility of LVH in women suggests that pressure reduction may be a useful intervention in women. Female LV chambers under increased load do not dilate compared with their male counterparts, which leads to higher estimated filling pressures, characteristic of HFpEF.³⁰ Although hypertension causes increased chamber stiffness in both men and women, it is persistently higher in women at any age.³¹ Noteworthy too is that younger women, aged 20 to 40 years, have enhanced diastolic function compared with men; this is reversed once women become >60 years of age.^{32,33} Finally, differences in vascular biology determine increased arterial stiffening in women comparatively.³ Even the lower range of LVEF for HFpEF is usually defined as an EF of $>50\%$, but a normal LVEF is typically higher in women, averaging 75% in women aged 30 to 65 years.²⁶ Perhaps a LVEF of 50% may, in fact, represent systolic dysfunction in women.^{26,34} The specific implications of these important sex differences for finding more definitive therapies for HFpEF are not clear. Nevertheless, in this era of phenomapping, the important phenotype of being woman should not be ignored.

The intersect between HF and AF is a collision of 2 epidemics.^{6,35,36} AF is consistently associated with HFpEF, whereas 65% of patients with HFpEF have AF.³⁵ Interestingly, although AF typically displays a male preponderance, women with HFpEF are equally affected by AF.^{35,37} Diastolic dysfunction has also been shown to be an independent predictor of AF. The pathophysiological and clinical implication of left atrial (LA) remodeling is significant in the HFpEF population. Effects of atrial abnormalities are atrial endocrine function, including natriuretic peptides; LA mechanoreceptor function in vasopressin production, water, and electrolyte balance; LA remodeling and increased collagen synthesis and fibrosis, thereby decreasing LA compliance; and the loss of atrial contraction, possibly influencing the reduced exercise tolerance in HFpEF.³⁸ Furthermore,

those with diastolic dysfunction undergoing AF ablation have a higher risk of AF recurrence.³⁹ Intriguingly, a recent clinical trial showed patients with HFpEF and dilated LA benefited more from carvedilol than patients without a dilated LA. The authors suggested that disease in the atria might be a target, as well as factor, in patient selection for HFpEF therapies.⁴⁰

A third important phenotype in a HFpEF cohort is obesity. Obesity, particularly central adiposity, influences LV geometry substantially more in women than in men.²⁶ In addition, adipose mass is greater in women compared with men.³⁴ A new HFpEF paradigm has proposed that frequently associated comorbidities, most significant being obesity, trigger a systemic inflammatory response that leads to increased oxidative stress in the coronary microvascular endothelium. The result is stiffer and more hypertrophied cardiomyocytes.⁴¹ Increased oxidative stress might also lead to increased myocardial fibrosis, both in the atria and the ventricles, a pathway linking obesity, HFpEF, and AF.

There are other pathophysiologically based pathways currently being investigated, including the degree of fibrosis and coronary microvascular rarefaction (loss of vessels either from destruction or lack of regeneration), both possibly related to oxidative stress in the coronary microvascular endothelium as discussed above.⁴² Although several possible new areas for exploration have been discussed, there are currently many promising areas being explored and the overlap of all these pathways will likely be the key.

Case to Begin Simply

Phenomapping and genomic typing are technologies that may introduce new paths of discovery; they are costly and not currently suitable for classifying patients in a large trial. The easily ascertained phenotypes of sex, obesity, and AF have been and are available now; sex is binary, whereas obesity and AF can be further divided into discrete subsets. These 3 clinical phenotypes (obesity, sex, and AF) are characterized by abnormal fibrosis and inflammatory responses that have been shown to be pathophysiologically related to patients diagnosed clinically with HFpEF. Thus, the first step must be to show that these 3 clinical phenotypes, separately and together, result in different outcomes for patients with HFpEF. Future mechanistic investigations about HFpEF should be focused on the overlap, instead of differences, with sex at the epicenter (Figure). Thus, extent of myocardial fibrosis could be examined in HFpEF women with and without AF or with various degrees of obesity. The physiological abnormalities delineated could then be linked, once again, to clinical outcomes. The power of applying our knowledge of sex differences in cardiac remodeling, vascular biology, and cardiac arrhythmias to the larger dilemma of the HFpEF syndrome is one that should not be overlooked. The phenotype of the frail woman with HFpEF may still be a powerful tool in understanding this vexing syndrome.

References

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makum DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D,

- Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics: 2011 update—a report from the American Heart Association. *Circulation*. 2011; 123:e18–e209. [PubMed: 21160056]
2. Alagiakrishnan K, Banach M, Jones LG, Datta S, Ahmed A, Aronow WS. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults. *Ann Med*. 2013; 45:37–50. DOI: 10.3109/07853890.2012.660493 [PubMed: 22413912]
 3. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. *Circulation*. 2011; 123:2006–2014. [PubMed: 21555723]
 4. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wan TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction; insights from the framingham heart study of the national heart, lung, and blood institute. *Circulation*. 2009; 119:3070–3077. [PubMed: 19506115]
 5. Masoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, Ordin DL, Krumholz HM. Gender, age, and heart failure with preserved left ventricular systolic function. *J Am Coll Cardiol*. 2003; 41:217–223. [PubMed: 12535812]
 6. Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure. *Circ Heart Fail*. 2013; 6:279–286. [PubMed: 23271790]
 7. Agha G, Loucks EB, Tinker LF, Waring ME, Michaud DS, Foraker RE, Li W, Martin LW, Greenland P, Manson JE, Eaton CB. Healthy lifestyle and decreasing risk of heart failure in women: the Women's Health Initiative observational study. *J Am Coll Cardiol*. 2014; 64:1777–1785. DOI: 10.1016/j.jacc.2014.07.981 [PubMed: 25443698]
 8. Brouwers FP, Hillege HL, van Gilst WH, van Veldhuisen DJ. Comparing new onset heart failure with reduced ejection fraction and new onset heart failure with preserved ejection fraction: an epidemiologic perspective. *Curr Heart Fail Rep*. 2012; 9:363–368. DOI: 10.1007/s11897-012-0115-7 [PubMed: 22968403]
 9. Velagaleti RS, Gona P, Pencina MJ, Aragam J, Wang TJ, Levy D, D'Agostino RB, Lee DS, Kannel WB, Benjamin EJ, Vasan RS. Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. *Am J Cardiol*. 2014; 113:117–122. DOI: 10.1016/j.amjcard.2013.09.028 [PubMed: 24210333]
 10. Paulus WJ, Tschope C, Sanderson TC, Rusconi C, Flachskamp FA, Rademakers FE, Marino P, Smiseth OA, De KG, Leite-Moreira AF, Borbel A, Edes I, Handoko ML, Heymans S, Pezzali N, Dickstein K, Fraswer AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology. *Eur Heart J*. 2007; 28:2539–2550. [PubMed: 17428822]
 11. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. *Circulation*. 2000; 101:2118–2121. [PubMed: 10790356]
 12. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Flippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitler J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirtes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P. Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. *Eur Heart J*. 2012; 33:1787–1847. [PubMed: 22611136]
 13. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschope C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Coats AJ,

Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *Eur Heart J*. 2014; 35:2797–2811. [PubMed: 25104786]

14. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. *Am Heart J*. 2011; 162:966–972. [PubMed: 22137068]
15. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet*. 2003; 362:777–781. [PubMed: 13678871]
16. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med*. 2008; 359:2456–2467. DOI: 10.1056/NEJMoa0805450 [PubMed: 19001508]
17. Wang AY, Wang M, Lam CW, Chan IH, Lui SF. Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis. *Am J Kidney Dis*. 2013; 61:975–983. [PubMed: 23474006]
18. Caughey MC, Avery CL, Ni H, Solomon SD, Matsushita K, Wruck LM, Rosamond WD, Loehr LR. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). *Am J Cardiol*. 2014; 114:1850–1854. DOI: 10.1016/j.amjcard.2014.09.024 [PubMed: 25438912]
19. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. *J Am Coll Cardiol*. 2006; 47:76–84. DOI: 10.1016/j.jacc.2005.09.022 [PubMed: 16386668]
20. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. *Circulation*. 2015; 131:269–279. DOI: 10.1161/CIRCULATIONAHA.114.010637 [PubMed: 25398313]
21. Rossignol P, Zannad F. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but East does not meet West. *Circulation*. 2015; 131:7–10. DOI: 10.1161/CIRCULATIONAHA.114.013637 [PubMed: 25406307]
22. Kristensen SL, Køber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS, Zile MR, Granger CB, Wikstrand J, Komajda M, Carson PE, Pfeffer MA, Swedberg K, Wedel H, Yusuf S, McMurray JJ. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. *Circulation*. 2015; 131:43–53. DOI: 10.1161/CIRCULATIONAHA.114.012284 [PubMed: 25406306]
23. Damman K, Perez AC, Anand IS, Komajda M, McKelvie RS, Zile MR, Massie B, Carson PE, McMurray JJ. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. *J Am Coll Cardiol*. 2014; 64:1106–1113. DOI: 10.1016/j.jacc.2014.01.087 [PubMed: 25212644]
24. Mohammed SF, Hussain I, Abou Ezzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. *Circulation*. 2014; 130:2310–2320. DOI: 10.1161/CIRCULATIONAHA.113.008461 [PubMed: 25391518]
25. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. *J Am Coll Cardiol*. 2014; 64:541–549. DOI: 10.1016/j.jacc.2014.05.030 [PubMed: 25104521]
26. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM, Levine BD, Drazner MH. Women have higher left ventricular ejection fractions than men independent of

- differences in left ventricular volume: the dallas heart study. *Circulation*. 2006; 113:1597–1604. [PubMed: 16567580]
27. de Simone F, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. *Hypertension*. 1995; 26:979–983. [PubMed: 7490158]
 28. Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients >60 years of age with aortic stenosis. *Am J Cardiol*. 1994; 74:794–798. [PubMed: 7942552]
 29. Petrov G, Regitz-Zagrosek V, Lehmkuhl E, Krabatsch T, Dunkel A, Dandel M, Dworatzek E, Mahmoodzadeh S, Schubert C, Becher E, Hampl H, Hetzer R. Regression of myocardial hypertrophy after aortic valve replacement: faster in women? *Circulation*. 2010; 122:S23–S28. [PubMed: 20837918]
 30. Fleg JL, O'Connor F, Gerstenblith G, Becker LC, Clulow J, Schulman SP, Lakatta EG. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. *J Appl Phys*. 1995; 78:890–900.
 31. Rossi P, Francès Y, Kingwell BA, Ahimastos AA. Gender differences in artery wall biomechanical properties throughout life. *J Hypertens*. 2011; 29:1023–1033. DOI: 10.1097/HJH.0b013e328344da5e [PubMed: 21346620]
 32. Grandi A, Venco A, Barzizza F, Scalise F, Pantaleo P, Finardi G. Influence of age and sex on left ventricular anatomy and function in normals. *Cardiology*. 1992; 81:8–13. [PubMed: 1477859]
 33. Föll D, Jung B, Schilli E, Staehle F, Geibel A, Hennig J, Bode C, Markl M. Magnetic resonance tissue phase mapping of myocardial motion: new insight in age and gender. *Circ Cardiovasc Imaging*. 2010; 3:588–595.
 34. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? *Curr Opin Cardiol*. 2011; 26:562–568. DOI: 10.1097/HCO.0b013e32834b7faf [PubMed: 21993357]
 35. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Löfman I, Ennezat PV, Sportouch-Dukhan C, Drouet E, Daubert JC, Linde C. KaRen Investigators. Association between cardiovascular vs non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. *Eur J Heart Fail*. 2014; 16:992–1001. DOI: 10.1002/ejhf.137 [PubMed: 25046483]
 36. Oluleye OW, Rector TS, Win S, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Massie B, Carson PE, Anand IS. History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. *Circ Heart Fail*. 2014; 7:960–966. DOI: 10.1161/CIRCHEARTFAILURE.114.001523 [PubMed: 25225241]
 37. Renoux C, Patenaude V, Suissa S. Incidence, mortality, and sex differences of non-valvular atrial fibrillation: a population-based study. *J Am Heart Assoc*. 2014; 3:e001402.doi: 10.1161/JAHA.114.001402 [PubMed: 25366150]
 38. Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail*. 2014; 7:1042–1049. DOI: 10.1161/CIRCHEARTFAILURE.114.001276 [PubMed: 25415957]
 39. Kumar P, Patel A, Mounsey JP, Chung EH, Schwartz JD, Pursell IW, Gehi AK. Effect of left ventricular diastolic dysfunction on outcomes of atrial fibrillation ablation. *Am J Cardiol*. 2014; 114:407–411. DOI: 10.1016/j.amjcard.2014.05.012 [PubMed: 24948489]
 40. Yamamoto K, Origasa H, Suzuki Y, Takahashi T, Shinozaki T, Watanabe T, Sakata Y, Izumi C, Taira K, Hori M. J-DHF Investigators. Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction—a report from the Japanese Diastolic Heart Failure Study (J-DHF). *J Cardiol*. 2014; 63:424–431. DOI: 10.1016/j.jjcc.2013.10.014 [PubMed: 24286855]
 41. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction. *Am J Coll Cardiol*. 2013; 62:263–271.
 42. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. *Circulation*. 2014 (epub ahead of print).

Figure.

The overlap of heart failure with preserved ejection fraction (HFpEF) phenotypes for sex, obesity, and atrial fibrillation.

Table**HFpEF Classification**

European Study Group on Diastolic Heart Failure¹⁰	Framingham¹¹	ESC Guidelines¹²
Lung crepitation, pulmonary edema, ankle swelling, dyspnea on exertion, and fatigue	Clinical signs and symptoms, supportive laboratory tests (chest x-ray), and typical response to treatment with diuretics	Symptoms: breathlessness, ankle swelling, and fatigue; Signs: elevated jugular venous pressure, pulmonary crackles, and displaced apex beat
Objectively reduced peak $\dot{V}_{O_2}$ (<25 mL/kg/min) or 6-min walk test (<300 m)	LVEF >50% within 72 h of HF	Normal LVEF with LV not dilated
LVEF >50%	Diastolic assessment not required	Relevant structural heart disease (LVH/LA enlargement) and diastolic dysfunction
Evidence of abnormal LV relaxation, filling, and diastolic distensibility	...	...

ESC indicates European Society of Cardiology; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; and LVH, left ventricular hypertrophy.

Adapted From Senni et al¹³ with permission of the publisher. Copyright © 2015, Oxford University Press.